Arcus Biosciences RCUS 深 滬
等待開盤 10-30 09:30:00 美东时间
20.29
+0.410
+2.06%
華盛通- 最 高22.1099
- 今 開20.00
- 成交量 214.14万股
- 最 低 19.80
- 昨 收 19.88
- 總市值 21.51亿
- 52周最高 22.1099
- 市盈率 靜 --
- 換手率 2.02%
- 52周最低 6.50
- 委 比 55.56%
- 總股本 1.06亿
- 歷史最高 49.10
- 量 比 1.55
- 振 幅 11.62%
- 歷史最低 6.30
- 每 手 1
- 風險率 3.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
53分钟前
Analyst Expectations For Arcus Biosciences's Future
Throughout the last three months, 5 analysts have evaluated Arcus Biosciences (...
10-29 19:45
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $24 to $28.
10-29 19:03
Arcus Biosciences Reports Promising Q3 2025 Results
Arcus Biosciences ( ($RCUS) ) has released its Q3 earnings. Here is a breakdown...
10-29 14:51
Arcus Biosciences Q3 EPS $(1.27) Beats $(1.33) Estimate, Sales $26.000M Beat $21.400M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.33) by 4.3 percent. This is a 27 percent decrease over losses of $(1.00) per share from the
10-29 04:39
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Gilead Sciences Completes Promising Study on Metastatic Colorectal Cancer Treatment
Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. ...
10-21 00:30
期权扫描 | 大涨9.4%，AMD期权成交持续放量；一看涨期权涨超4倍！SMR期权交易火爆
隔夜大涨9.4%，AMD期权成交持续放量；一看涨期权涨超4倍！SMR期权交易火爆；MARA与MSTR期权交易持续活跃>>
10-16 17:01
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $47 to $54.
10-14 01:47
